Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism

doi:10.12047/j.cjap.5685.2018.117

Abstract

Abstract: Objective: To investigate the effects of Birinapant on hepatocellular carcinoma cells and its related molecular mechanisms.Methods: Human hepatocellular carcinoma cells QGY-7701 were treated with 0, 1, 5, 25 and 125 nmol/L Birinapant for 24, 48 and 72 hours respectively, each experiment 3 wells.The proliferation activity of cells, the apoptosis levels, the cells nuclear type, the mitochondrial membrane potential, the transcription and expression levels of genes and the cytotoxicity of Birinapant were analyzed.At the same time, 4-week-old male BALB/C mice were randomly divided into 5 groups, with 20 mice in each group.The mice were inguinal injected with QGY-7701 cells, and then subcutaneous injected with Birinapant (concentrations ranging from 0, 1, 5, 25, 125 μg/kg) in each group after two days, once every other day.On 18^th day since first Birinapant injection, 10 mice were killed in each group to weigh tumor tissue and survival time was recorded from the remaining 10 mice.The effects of Birinapant on the growth of the tumor and the survival time of tumor-bearing mice were observed.Results: Compared with the negative control (NC) group, the proliferation activity of QGY-7701 was inhibited significantly after Birinapant treatment and the apoptosis levels were increased significantly (P<0.01).The cell mitochondrial membrane potential was decreased and the karyotype was changed (P<0.01).At the same time, the transcription and expression levels of genes cellular inhibitor of apoptosis protein 1(cIAP-1), cellular inhibitor of apoptosis protein 2(cIAP-2), ras, raf, mek and erk were significantly decreased (P<0.01), while the expression levels of caspase-3 and caspase-9 genes were up-regulated (P<0.01).Compared with the model group (MG), the growth of the tumor was inhibited significantly and the survival time of the tumor-bearing mice was prolonged after Birinapant treatment (P<0.01).Conclusion: Birinapant can inhibit the expression of cIAP-1, cIAP-2 and the proteins of Ras-Raf-MEK-ERK signal pathways, so as to activate the mitochondria mediated endogenous apoptosis pathway.Birinapant shows a certain inhibitory effect on liver cancer.

Key words: liver cancer, Smac analogue, Birinapant, proliferation, apoptosis, mice

JIANG Pan-ruo, KE Rui-jun, ZHU Ming-liao, LOU En-zhe, XIE Jia-geng, CHEN Jia-yu. Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism[J]. CJAP, 2018, 34(6): 524-529.

References

[1] Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level:results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12):1683-1691.
[2] Singh B, Jang Y, Maharjan S, et al. Combination therapy with doxorubicin-loaded galactosylated poly (ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer[J]. Biomaterials, 2017, 116:130-144.
[3] 高园, 聂鸿靖, 杨栋, 等. 肝癌患者单个核细胞线粒体DNA拷贝数与抗氧化能力的变化[J]. 中国应用生理学杂志, 2016, 32(1):1-5.
[4] Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J]. Proc Natl Acad Sci U S A, 2015, 112(18):5803-5808.
[5] Carter BZ, Mak PY, Mak DH, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents[J]. J Natl Cancer Inst, 2014, 106(2):djt440.
[6] Krepler C, Chunduru SK, Halloran MB, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells[J]. Clin Cancer Res, 2013, 19(7):1784-1794.
[7] Allensworth JL, Sauer SJ, Lyerly HK, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP dependent and TNF-α independent mechanism[J]. Breast Cancer Res Treat, 2013, 137(2):359-371.
[8] Sarosiek KA, Fraser C, Muthalagu N, et al. Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics[J]. Cancer Cell, 2017, 31(1):142-156.
[9] Elsayed NMY, Abou El Ella DA, Serya RAT, et al. Targeting apoptotic machinery as approach for anticancer therapy:Smac mimetics as anticancer agents[J]. Future J Pharmaceutical Sciences, 2015, 1(1):16-21.
[10] Fulda S.Smac mimetics to therapeutically target IAP proteins in cancer[J]. Int Rev Cell Mol Biol, 2017, 330:157-169.
[11] Cai J, Lin Y, Zhang H, et al. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics[J]. Proc Natl Acad Sci U S A, 2017, 114(26):6812-6817.
[12] Srivastava AK, Jaganathan S, Stephen L, et al. Effect of a Smac Mimetic (TL32711, Birinapant) on the apoptotic program and apoptosis biomarkers examined with validated multiplex immunoassays fit for clinical use[J]. Clin Cancer Res, 2016, 22(4):1000-1010.
[13] Nguyen QD, Lavdas I, Gubbins J, et al. Temporal and spatial evolution of therapy induced tumor apoptosis detected by caspase-3-selective molecular imaging[J]. Clin Cancer Res, 2013, 19(14):3914-3924.
[14] 黄林静, 张聪聪, 赵美平, 等. MAPK信号通路对大鼠低氧性PASMCs增殖、凋亡的调控[J]. 中国应用生理学杂志, 2017, 33(3):226-230.
[15] Maik-Rachline G, Seger R.The ERK cascade inhibitors:Towards overcoming resistance[J]. Drug Resist Updat, 2016, 25:1-12.
[16] Suzuki R, Kikuchi S, Harada T, et al. Combination of a selective HSP90α/β inhibitor and a RAS-RAF-MEK-ERK signaling pathway inhibitor triggers synergistic cytotoxicity in multiple myeloma cells[J]. Plos One, 2015, 10(12):e0143847.
[17] Butler DE, Marlein C, Walker HF, et al. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer[J]. Oncotarget, 2017, 8(34):56698-56713.
[18] Burdeos GC, Ito J, Eitsuka T, et al. δ and γ tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling[J]. Food Funct, 2016, 7(10):4170-4174.